Evidence map›Paper›PMID 27788205›Full record

ArticlePloS one2016

A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation.

Bridgette Janine Connell, Sui-Yuan Chang, Ekambaranellore Prakash, Rahima Yousfi, Viswaraman Mohan, Wilfried Posch, Doris Wilflingseder, Christiane Moog, Eiichi N Kodama, Pascal Clayette and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Antiviral Therapeutic Potential of Curcumin: An Update.Molecules (Basel, Switzerland) · 2021
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 5 countries.

Bridgette Janine ConnellInstitut de Biologie Structurale, UMR 5075, Univ. Grenoble Alpes, CNRS, CEA, F-38027 Grenoble, France.
Sui-Yuan ChangSchool of Medical Technology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Ekambaranellore PrakashIndus Biotech Pvt Ltd, Pune, India.
Rahima YousfiLaboratoire de Neurovirologie, Bertin Pharma, CEA, 92265 Fontenay aux Roses, France.
Viswaraman MohanIndus Biotech Pvt Ltd, Pune, India.
Wilfried PoschDivision of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria.
Doris WilflingsederDivision of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria.
Christiane MoogINSERM U1110, Fédération de médecine translationnelle de Strasbourg (FMTS), Institut de Virologie, 3 rue Koeberlé, 67000 Strasbourg, France.
Eiichi N KodamaDivision of Emerging Infectious Diseases, Miyagi Communitiy Health Promotion, Tohoku University School of Medicine, Bldg. 1, Rm. 515, 2-1 Seiryocho, Aoba-ku, Sendai 980-8575, Japan.
Pascal ClayetteLaboratoire de Neurovirologie, Bertin Pharma, CEA, 92265 Fontenay aux Roses, France.
Hugues Lortat-JacobInstitut de Biologie Structurale, UMR 5075, Univ. Grenoble Alpes, CNRS, CEA, F-38027 Grenoble, France.
CEA Grenoble · FRIndus Biotech (India) · INInnsbruck Medical University · ATCEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut de Virologie · FRNational Taiwan University Hospital · TWTohoku University · JP

Funding

Austrian Science Fund FWF P 25389
6 · The paper itself

Abstract

Amongst the many strategies aiming at inhibiting HIV-1 infection, blocking viral entry has been recently recognized as a very promising approach. Using diverse in vitro models and a broad range of HIV-1 primary patient isolates, we report here that IND02, a type A procyanidin polyphenol extracted from cinnamon, that features trimeric and pentameric forms displays an anti-HIV-1 activity against CXCR4 and CCR5 viruses with 1-7 μM ED50 for the trimer. Competition experiments, using a surface plasmon resonance-based binding assay, revealed that IND02 inhibited envelope binding to CD4 and heparan sulphate (HS) as well as to an antibody (mAb 17b) directed against the gp120 co-receptor binding site with an IC50 in the low μM range. IND02 has thus the remarkable property of simultaneously blocking gp120 binding to its major host cell surface counterparts. Additionally, the IND02-trimer impeded up-regulation of the inhibitory receptors Tim-3 and PD-1 on CD4+ and CD8+ cells, thereby demonstrating its beneficial effect by limiting T cell exhaustion. Among naturally derived products significantly inhibiting HIV-1, the IND02-trimer is the first component demonstrating an entry inhibition property through binding to the viral envelope glycoprotein. These data suggest that cinnamon, a widely consumed spice, could represent a novel and promising candidate for a cost-effective, natural entry inhibitor for HIV-1 which can also down-modulate T cell exhaustion markers Tim-3 and PD-1.

Indexed as

Anti-HIV AgentsBiflavonoidsBinding SitesCatechinCD4 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCinnamomum zeylanicumHeparan SulfateHepatitis A Virus Cellular Receptor 2HIV Envelope Protein gp120HumansProanthocyanidinsProgrammed Cell Death 1 ReceptorT-LymphocytesUp-RegulationAnti-HIV AgentsBiflavonoidsCatechinCD4 AntigensHAVCR2 protein, humanHeparan SulfateHepatitis A Virus Cellular Receptor 2HIV Envelope Protein gp120IND02 polymerPDCD1 protein, humanProanthocyanidinsprocyanidinProgrammed Cell Death 1 Receptor

Identifiers

PMID27788205
PMCPMC5082894
OpenAlexW2544540054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.